/Investor DB

Panacea Venture

Venture capital

Singapore · Seed–Late Stage · 22 people tracked

Find your way into Panacea Venture

Sign up to see every warm intro you have to Panacea Venture

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Panacea Venture team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

Panacea Venture backs innovative assets, breakthrough technologies, and scientific discoveries with the potential to address unmet medical needs and improve quality of life globally. Founded by partners who spun out of Kleiner Perkins, the firm applies deep life sciences experience to global company building and invests across every geography. It has raised three USD funds from institutional and strategic investors and holds investments in more than 30 private companies and several public companies, engaging from company formation through expansion-stage and public-market investing.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Late Stage
HQ
Singapore, SG
Instruments
Equity
Founded
2017
Private fund assets
$149.9M
Tracked investments
43
IPOs
1

Team · 22 people

from the firm's website & public directories
Hai Mi· General Partner
Delia Ding· Chief Financial Officer

Previously Finance Director at KPCB China. Holds a BA in accounting from Tongji University.

What they invest in

from 17 of 43 portfolio companies

Biotech ×17Healthtech ×8Deep Tech ×5Medical Devices ×5AI & Machine Learning ×3Digital Health ×3Longevity ×2Advanced Manufacturing ×1

HQs:United States×8China×1Taiwan×1

Investments · 43 tracked

founders shown can be your intro path

By year:2022 · 22018 · 13 dated

Windtree Therapeutics INC /DeOTC: WINT

BiotechWarrington, US

Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)John Tattory(Executive Officer)George Cox(Executive Officer)in

Co-investorsAgent Capital

Eosbioinnovationeosbioinnovation.com✓ verified

Eos BioInnovation invests in early-stage regenerative medicine therapies and technologies, focusing on cell, gene, and tissue therapies that target disease causes.

BiotechDeep TechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Brock ReeveJames(Founder and Managing Partner of Panacea Venture)

Apeiron Therapeuticsapeiron-bio.comin

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechBurlingame, US

Mingxi Li(CEO)inFred Aswad(Chief Scientific Officer)in

Co-investorsSofinnova Ventures

Chime Biologicschimebiologics.comin

Chime Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end support for biologics production, from cell line development through clinical and commercial manufacturing.

Advanced ManufacturingAI & Machine LearningBiotechSaaSWuhan, CN

Dr. Wei(Board Director and CEO)Jimmy Wei(President)in

Coastar Therapeutics, Inccoastartherapeutics.com

Coastar Therapeutics develops gene delivery technologies using erythrocyte-derived membranes to enable genetic medicines for cancer immunotherapy and gene therapies.

BiotechDeep TechHealthtech

Dr. Han LimDr. Luo

Convexiaconvexia.bioinSeed

Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity.

AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US

Ayaan Parikh(CEO)inRahul Vijayan(CTO)inAyaan Parikh Rahul Vijayan(Founder)

Co-investorsGravityMaiora Rebel VenturesY CombinatorAliaksandr HudzilinBasis Set VenturesBlast.Club+6 more

Domain Therapeuticsdomaintherapeutics.comin𝕏May 2022 · $42M

Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.

BiotechDigital Health

Co-investors3B Future Health FundCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalSeventure Partners

Evox Therapeuticsevoxtherapeutics.comin𝕏

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.

BiotechDeep Tech

Co-investorsGV (Google Ventures)OrbiMedOxford Science EnterprisesCowen Healthcare InvestmentsREDMILE

HanchorBiohanchorbio.comin

HanchorBio is a biotech company developing innovative immunotherapy drugs for cancer treatment through translational medicine, moving from early research to clinical applications.

BiotechHealthtechMedical DevicesTaiwan, TW

Co-investorsVivo CapitalKorea Investment Partners

hC Biosciencehcbioscience.comNov 2022Defunct

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

Leslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in

Co-investorsARCH Venture Partners5AM Ventures8VCAtlas VentureTaiho Ventures, LLCTakeda Ventures

MAAVRXmaavrx.com

A biotech company developing gene therapy treatments for neurodegenerative diseases.

BiotechDigital HealthLongevityMedical Devices

Mike McDonald(Founder and CEO)in

Neurochaseneurochase.comin𝕏

Neurochase provides consultancy to biotech and pharmaceutical companies on directly delivering therapies to the central nervous system, drawing on experience with catheter infusions and convection-enhanced delivery.

BiotechHealthtechMedical Devices

Sharon Kanein

Panaceacapitalpanaceacapital.com

Panacea Capital is a venture capital firm, spun out from Kleiner Perkins, that invests in life sciences and healthcare innovation across all geographies.

Biotech

Regatta Bioregatta.bioin

Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions.

BiotechHealthtech

Tactiva Therapeuticstactivatherapeutics.com

Tactiva Therapeutics develops immuno-oncology treatments using adoptive cell therapy approaches for cancer patients.

BiotechHealthtechMedical DevicesChicago, US

Richard C. Koya(Co-Founder)Kunle Odunsi(Co-Founder)Jay Zhang(CEO)

Co-investorsEFung CapitalVI Partners

XW Pharmaxwpharma.comin

XWPharma develops internally discovered small-molecule medicines, focusing on new chemical entities that target time-regulated neurobiology to treat neurological conditions.

Biotech

Co-investorsWI Harper Group

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Affection Animal PharmaceuticalsAffection Animal Pharmaceuticals AapAnimal vaccine R&D companyAnivia Medical HoldingsBase TherapeuticsBioFront TherapeuticsBiographFeng BiosciencesGT Apeiron TherapeuticsHarvest Integrated Research Organization (HiRO)Human LongevityInnovative Regenerative MedicineJuventas TherapeuticsKainova TherapeuticsKindstar GlobalLightning BiotherapeuticsManaolana OncologyMirageneMyrtelleNeuInventReal Star RehabilitationST Phi TherapeuticsTaiLai BiosciencesTriArm TherapeuticsVelaVigoWindtree TherapeuticsZhaoke Ophthalmology

Exits · 1

1 IPOs

Windtree Therapeutics INC /DeOTC: WINT

Portfolio news

latest coverage across their companies

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

CompanyOwnedIPO priceAt IPOStake value
Windtree Therapeutics INC /De7.6%$2.93Apr 2023$202.1K

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has Panacea Venture made?
Panacea Venture has 43 tracked investments, 1 of which have exited.
What stage does Panacea Venture invest at?
Panacea Venture invests at the Seed, Series A, Series B, Growth, Late Stage stages.
What sectors does Panacea Venture focus on?
Panacea Venture focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Panacea Venture located?
Panacea Venture is headquartered in Singapore, SG.
Who does Panacea Venture co-invest with?
Panacea Venture most often shares deals with WI Harper Group, GV (Google Ventures), Investcorp, among 8 tracked co-investors.

Images

Panacea Venture photo

Similar investors

Featured in lists